IBDEI1JP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27437,0)
 ;;=396.3^^162^1781^6
 ;;^UTILITY(U,$J,358.3,27437,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27437,1,4,0)
 ;;=4^396.3
 ;;^UTILITY(U,$J,358.3,27437,1,5,0)
 ;;=5^Aortic And Mitral Insufficiency
 ;;^UTILITY(U,$J,358.3,27437,2)
 ;;=Aortic and Mitral Insufficiency^269583
 ;;^UTILITY(U,$J,358.3,27438,0)
 ;;=414.3^^162^1781^15
 ;;^UTILITY(U,$J,358.3,27438,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27438,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,27438,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,27438,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,27439,0)
 ;;=453.9^^162^1781^82
 ;;^UTILITY(U,$J,358.3,27439,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27439,1,4,0)
 ;;=4^453.9
 ;;^UTILITY(U,$J,358.3,27439,1,5,0)
 ;;=5^Venous Thrombosis NOS
 ;;^UTILITY(U,$J,358.3,27439,2)
 ;;=^39455
 ;;^UTILITY(U,$J,358.3,27440,0)
 ;;=453.89^^162^1781^79
 ;;^UTILITY(U,$J,358.3,27440,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27440,1,4,0)
 ;;=4^453.89
 ;;^UTILITY(U,$J,358.3,27440,1,5,0)
 ;;=5^Venous Embolism,Acute NEC
 ;;^UTILITY(U,$J,358.3,27440,2)
 ;;=^338259
 ;;^UTILITY(U,$J,358.3,27441,0)
 ;;=453.79^^162^1781^80
 ;;^UTILITY(U,$J,358.3,27441,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27441,1,4,0)
 ;;=4^453.79
 ;;^UTILITY(U,$J,358.3,27441,1,5,0)
 ;;=5^Venous Embolism,Chr NEC
 ;;^UTILITY(U,$J,358.3,27441,2)
 ;;=^338251
 ;;^UTILITY(U,$J,358.3,27442,0)
 ;;=425.11^^162^1781^57
 ;;^UTILITY(U,$J,358.3,27442,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27442,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,27442,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,27442,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,27443,0)
 ;;=425.18^^162^1781^22
 ;;^UTILITY(U,$J,358.3,27443,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27443,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,27443,1,5,0)
 ;;=5^Cardiomyopathy,Hypertrophic
 ;;^UTILITY(U,$J,358.3,27443,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,27444,0)
 ;;=V12.55^^162^1781^52
 ;;^UTILITY(U,$J,358.3,27444,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27444,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,27444,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,27444,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,27445,0)
 ;;=414.4^^162^1781^14
 ;;^UTILITY(U,$J,358.3,27445,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27445,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,27445,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,27445,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,27446,0)
 ;;=271.3^^162^1782^11
 ;;^UTILITY(U,$J,358.3,27446,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27446,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,27446,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,27446,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,27447,0)
 ;;=611.1^^162^1782^16
 ;;^UTILITY(U,$J,358.3,27447,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27447,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,27447,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,27447,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,27448,0)
 ;;=704.1^^162^1782^17
 ;;^UTILITY(U,$J,358.3,27448,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27448,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,27448,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,27448,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,27449,0)
 ;;=251.2^^162^1782^29
 ;;^UTILITY(U,$J,358.3,27449,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,27449,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,27449,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,27449,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,27450,0)
 ;;=257.2^^162^1782^30
 ;;^UTILITY(U,$J,358.3,27450,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI1JP
